Navigation Links
R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Date:10/24/2007

ges in hematologic or other laboratory parameters.

Part 3 is a multi-center, observer-blinded, within-cohort randomized, placebo-controlled study being conducted in up to 75 treatment-naive patients with genotype 1 hepatitis C virus. The primary objective is to assess the safety, tolerability and pharmacokinetics of R7128 in combination with Pegasys plus Copegus. The secondary objective of Part 3 is to evaluate the short-term change in HCV RNA. The study will include two to three oral doses of R7128 (500 mg to 1500 mg) that are being administered twice-daily with Pegasys plus Copegus for 28 days.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and liver transplants. The WHO estimates that nearly 180 million people worldwide, or approximately 3% of the world's population, are infected with hepatitis C virus (HCV). The CDC has reported that almost four million people in the United States have been infected with HCV, of whom 2.7 million are chronically infected.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that the FDA withdraws the R7128 fast track designation, the risk that the FDA does not expedite the review or approval of any application for R7128, the risk that adverse events could cause the cessation of the Phase 1 study and/or our development of R7128, the risk that our collaboration with Roche will not continue or
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
10. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
11. Point of Care Strep Tests Speed Treatment, Lower Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets ... Drugs - Global Strategic Business Report" report to their ... for Human Growth Hormone Drugs in US$ Million by the ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim ... Administration (FDA) accepted for review the New Drug ... tiotropium and olodaterol delivered via the Respimat ® ... once-daily maintenance treatment of airflow obstruction in patients ... bronchitis and/or emphysema. Tiotropium + olodaterol FDC will ...
(Date:8/19/2014)... Aug. 19, 2014  Stryker Corporation,s Orthopaedics Division, the Official ... is bringing its message of joint health to golf fans ... this week at The Barclays.  The company,s fan destination ... Spectator Village near the 17 th fairway at the ... on Thursday, August 21 st .    At ...
Breaking Medicine Technology:Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5
... 31, 2011 Boston Scientific Corporation (NYSE: ... Food and Drug Administration (FDA) has approved its ... and delivery of diagnostic, embolic and therapeutic materials ... be used by interventional radiologists for minimally invasive ...
... Endologix, Inc. (Nasdaq: ELGX ), ... announced today the publication of favorable clinical results ... of abdominal aortic aneurysm (EVAR).  The peer-reviewed article ... trial, with successful aneurysm exclusion in all patients, ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 2Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 3Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 4Endologix Announces Favorable Clinical Results for Nellix Technology 2Endologix Announces Favorable Clinical Results for Nellix Technology 3
(Date:8/20/2014)... 20, 2014 BCC Research ( ... PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS ... is expected to grow to $15.2 billion by ... (CAGR) of 15.9%. Increasing industrialization is driving ... a rapidly expanding range of industrial applications such ...
(Date:8/20/2014)... A Missouri federal judge has remanded a lawsuit filed ... GranuFlo and NaturaLyte to the City of St. Louis Circuit ... The judge rejected an assertion by the defendants that the ... et al. v. Fresenius Medical Care North America Inc., et ... the manufacturer of the dialysis products GranuFlo and NaturaLyte. In ...
(Date:8/20/2014)... (HealthDay News) -- Leaving the car at home and getting ... for your health, a new study indicates. Researchers looked ... that 76 percent of men and 72 percent of women ... of women used public transit, and 14 percent of men ... who drove to work weighed more and had higher levels ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... leading nonprofit authority on the use of health ... announced the full agenda for its annual fall ... IT Efficiency. WEDI-Con 2014 will take place at ... 20-23, 2014, attracting a diverse cross-section of payers, ...
(Date:8/20/2014)... Parents and kids across the nation are ... means buying textbooks and arranging after school care, there ... part of the annual re-commitment to your child’s education; ... Association, 27% of students say they experience "extreme stress" ... are stressed by school pressures. The study, Stress in ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:GranuFlo/NaturaLyte Case Remanded to State Court By Missouri Federal Judge, Baron and Budd Reports 2Health News:Want to Stay Slim? Leave the Car at Home 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 2Health News:Five Easy Steps to Help Your Child Manage Back-to-school Stress 3
... Resuscitating hopelessly ill patients too slowly to save their ... prolongs death and suffering, according to the November issue ... Jacinta Kelly, from Trinity College Dublin, has called for ... the practice of slow codes and highlighted the need ...
... Ellex Medical Lasers,Limited (ASX: ELX), a global leader ... ultrasound systems, announced today that the initial,results of ... be presented by Peter Hamilton MD, FRCOph at ... which takes place,November 10-13, in New Orleans. Dr. ...
... Amira Pharmaceuticals, a small,molecule pharmaceutical company focused on ... disease linked to the eicosanoid pathway,today announced the ... development. Dr. Raizon-Ounis brings 20 years of ... clinical research & licensing executive with,Roche Palo Alto. ...
... convenience for on-the-go snacking, COLUMBUS, Ohio, ... ),today announced the launch of new Fruitified(TM) ... four,great-tasting flavors: Apple Cinnamon, Blueberry, Banana Nut ... an excellent source of,protein and calcium and ...
... play role in autism, asthma,and other chronic health ... National Autism,Association (NAA) announced today a nationwide initiative ... program created by,the Deirdre Imus Environmental Center for ... to eliminate the serious,dangers posed to children from ...
... to the Third Quarter of 2006- ... During the Quarter-, PRINCETON, N.J., Nov. 1 Orchid ... identity DNA testing,services, today reported its financial results for the ... the third quarter of 2007,compared to $15.7 million for the ...
Cached Medicine News:Health News:Token resuscitation attempts on hopelessly ill patients prolong suffering 2Health News:Token resuscitation attempts on hopelessly ill patients prolong suffering 3Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 2Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 3Health News:Ellex Announces New Retina Regeneration Therapy to be Presented at the AAO 4Health News:Amira Pharmaceuticals Appoints First Vice President of Development 2Health News:Abbott Launches Fruitified(TM) ZonePerfect(R) All-Natural Nutrition Bars 2Health News:Abbott Launches Fruitified(TM) ZonePerfect(R) All-Natural Nutrition Bars 3Health News:National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National 'Greening Your School' Initiative 2Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 2Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 3Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 4Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 5Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 6Health News:Orchid Cellmark Reports Third Quarter 2007 Financial Results 7
... Nebulizer Prefilled 750ML Sterile H 2 O ... with sterile water for inhalation, these humidifier systems ... which makes a round opening for secure attachment ... designed to help prevent particulate from reaching oxygen ...
... 35%-100% FIO2, ,Empty Nebulizer 002002 has ... It has ports for a feed set ... 5007P and 5207 have FIO2 settings adjustable ... slip-on heaters are also available to provide ...
... , One device provides both ... from a single gas source , ... the number of SKUs dedicated to ... inconvenience of double or wye set ...
MISTY OX® Hi-Fi Nebulizer...
Medicine Products: